Liquidia (LQDA) Expected to Announce Quarterly Earnings on Monday

Liquidia (NASDAQ:LQDA - Get Free Report) will likely be posting its Q1 2025 quarterly earnings results before the market opens on Monday, May 12th. Analysts expect Liquidia to post earnings of ($0.42) per share and revenue of $3.23 million for the quarter.

Liquidia (NASDAQ:LQDA - Get Free Report) last issued its earnings results on Wednesday, March 19th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.08). The firm had revenue of $2.92 million during the quarter, compared to analysts' expectations of $4.60 million. Liquidia had a negative return on equity of 163.21% and a negative net margin of 765.38%. On average, analysts expect Liquidia to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Liquidia Stock Up 13.2 %

Shares of NASDAQ LQDA opened at $15.83 on Monday. The firm has a market cap of $1.35 billion, a P/E ratio of -9.71 and a beta of 0.24. Liquidia has a twelve month low of $8.26 and a twelve month high of $16.81. The company has a 50 day moving average of $14.22 and a 200 day moving average of $13.02.

Analyst Ratings Changes

A number of research analysts have recently issued reports on LQDA shares. Needham & Company LLC reaffirmed a "buy" rating and set a $25.00 price target on shares of Liquidia in a report on Thursday, April 10th. HC Wainwright restated a "buy" rating and set a $29.00 target price on shares of Liquidia in a research note on Thursday, March 20th. Finally, Scotiabank reiterated an "outperform" rating on shares of Liquidia in a research note on Thursday, March 20th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, Liquidia presently has a consensus rating of "Buy" and a consensus target price of $26.63.

Insider Buying and Selling at Liquidia

In other Liquidia news, CEO Roger Jeffs sold 14,130 shares of the stock in a transaction that occurred on Monday, April 14th. The shares were sold at an average price of $13.57, for a total value of $191,744.10. Following the transaction, the chief executive officer now directly owns 1,006,420 shares in the company, valued at approximately $13,657,119.40. This trade represents a 1.38 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, General Counsel Russell Schundler sold 5,964 shares of the business's stock in a transaction on Monday, April 14th. The shares were sold at an average price of $13.57, for a total transaction of $80,931.48. Following the sale, the general counsel now directly owns 570,301 shares of the company's stock, valued at approximately $7,738,984.57. The trade was a 1.03 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 33,138 shares of company stock worth $450,233 in the last three months. 30.10% of the stock is currently owned by company insiders.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.